Pre-procedural TMAO As a Predictor for Recurrence of Atrial Fibrillation After Catheter Ablation

Overview

Journal BMC Cardiovasc Disord

Publisher Biomed Central

Specialty Cardiology & Vascular Diseases

Date 2024 Dec 28

PMID 39732662

Authors

Siyu Meng

Tianyi Ni

Qiuyao Du

Mengjie Liu

Peibing Ge

Jin Geng

Bingjian Wang

Affiliations

Soon will be listed here.

Abstract

Background: Numerous studies have demonstrated the significance of trimethylamine-N-oxide (TMAO) in the progression of atrial fibrillation (AF). However, the association between TMAO and AF recurrence (RAF) post-catheter ablation is not yet fully understood. This study aims to elucidate the predictive capability of pre-procedural TMAO levels in determining RAF following catheter ablation (CA).

Methods: This study was conducted as a prospective, single-center observational study. Between June 2021 and June 2022, 152 patients from the Department of Cardiology at The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University were enrolled. Baseline characteristics and serum TMAO levels were assessed for all participants. Patients with AF who underwent CA were monitored for recurrences of AF using electrocardiography (ECG) or 24-hour Holter monitoring during the follow-up period.

Results: The study found that serum TMAO levels were significantly higher in persistent AF (PeAF) patients compared to those in sinus rhythm (SR) and paroxysmal AF (PaAF) patients (3.96 ± 1.69 vs. 1.81 ± 0.59, 3.02 ± 1.50 µM, P < 0.001 and P < 0.01, respectively). After a one-year follow-up, 29 (21.2%) AF patients experienced recurrence after CA. Multivariate Cox proportional hazards regression analysis revealed that pre-procedural serum TMAO was an independent predictor of recurrent AF (HR = 1.78, 95% CI = 1.43-2.21, P < 0.001). The receiver operating characteristic (ROC) curve analysis identified a cut-off value of 4.3µM for serum TMAO levels in predicting recurrent AF (area under the curve: 0.835, P < 0.001). The Kaplan-Meier plot demonstrated that patients with TMAO levels greater than 4.3µM had a significantly higher rate of recurrent AF (HR = 13.53, 95% CI = 6.19-29.56, P < 0.001).

Conclusion: Patients with AF exhibited elevated levels of circulating TMAO compared to patients with SR. The findings suggest a potential role of TMAO in the development of AF, with pre-procedural serum TMAO levels serving as a reliable predictor of recurrence of AF CA.

References

Nguyen B, Meems L, van Faassen M, Crijns H, van Gelder I, Kuipers F . Gut-microbe derived TMAO and its association with more progressed forms of AF: Results from the AF-RISK study. Int J Cardiol Heart Vasc. 2021; 34:100798. PMC: 8167185. DOI: 10.1016/j.ijcha.2021.100798. View

Erhard N, Metzner A, Fink T . Late arrhythmia recurrence after atrial fibrillation ablation: incidence, mechanisms and clinical implications. Herzschrittmacherther Elektrophysiol. 2022; 33(1):71-76. PMC: 8873127. DOI: 10.1007/s00399-021-00836-6. View

Zuo K, Li J, Fang C, Zhong J, Xu L, Yang X . Alterations of gut viral signals in atrial fibrillation: complex linkage with gut bacteriome. Aging (Albany NY). 2022; 14(16):6537-6553. PMC: 9467389. DOI: 10.18632/aging.204222. View

Schupack D, Mars R, Voelker D, Abeykoon J, Kashyap P . The promise of the gut microbiome as part of individualized treatment strategies. Nat Rev Gastroenterol Hepatol. 2021; 19(1):7-25. PMC: 8712374. DOI: 10.1038/s41575-021-00499-1. View

ODonnell J, Zheng T, Meric G, Marques F . The gut microbiome and hypertension. Nat Rev Nephrol. 2023; 19(3):153-167. DOI: 10.1038/s41581-022-00654-0. View

Walker R, Vlamakis H, Lee J, Besse L, Xanthakis V, Vasan R . Population study of the gut microbiome: associations with diet, lifestyle, and cardiometabolic disease. Genome Med. 2021; 13(1):188. PMC: 8680346. DOI: 10.1186/s13073-021-01007-5. View

Zou C, Zhang Z, Zhao W, Li G, Ma G, Yang X . Predictive value of pre-procedural autoantibodies against M2-muscarinic acetylcholine receptor for recurrence of atrial fibrillation one year after radiofrequency catheter ablation. J Transl Med. 2013; 11:7. PMC: 3551716. DOI: 10.1186/1479-5876-11-7. View

Zuo K, Liu X, Wang P, Jiao J, Han C, Liu Z . Metagenomic data-mining reveals enrichment of trimethylamine-N-oxide synthesis in gut microbiome in atrial fibrillation patients. BMC Genomics. 2020; 21(1):526. PMC: 7391570. DOI: 10.1186/s12864-020-06944-w. View

Mozaffarian D, Benjamin E, Go A, Arnett D, Blaha M, Cushman M . Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2014; 131(4):e29-322. DOI: 10.1161/CIR.0000000000000152. View

10.

Geng J, Zhang Y, Wang Y, Cao L, Song J, Wang B . Catheter ablation versus rate control in patients with atrial fibrillation and heart failure: A multicenter study. Medicine (Baltimore). 2017; 96(49):e9179. PMC: 5728981. DOI: 10.1097/MD.0000000000009179. View

11.

Tan Y, Zhou J, Liu C, Zhou P, Sheng Z, Li J . Association Between Plasma Trimethylamine N-oxide and Neoatherosclerosis in Patients With Very Late Stent Thrombosis. Can J Cardiol. 2020; 36(8):1252-1260. DOI: 10.1016/j.cjca.2019.10.041. View

12.

Gawalko M, Linz D, Dobrev D . Gut-microbiota derived TMAO: A risk factor, a mediator or a bystander in the pathogenesis of atrial fibrillation?. Int J Cardiol Heart Vasc. 2021; 34:100818. PMC: 8219839. DOI: 10.1016/j.ijcha.2021.100818. View

13.

Hu T, Wu Q, Yao Q, Jiang K, Yu J, Tang Q . Short-chain fatty acid metabolism and multiple effects on cardiovascular diseases. Ageing Res Rev. 2022; 81:101706. DOI: 10.1016/j.arr.2022.101706. View

14.

Zhang Y, Zhang S, Li B, Luo Y, Gong Y, Jin X . Gut microbiota dysbiosis promotes age-related atrial fibrillation by lipopolysaccharide and glucose-induced activation of NLRP3-inflammasome. Cardiovasc Res. 2021; 118(3):785-797. DOI: 10.1093/cvr/cvab114. View

15.

Dai H, Hou T, Wang Q, Hou Y, Zhu Z, Zhu Y . Roles of gut microbiota in atrial fibrillation: insights from Mendelian randomization analysis and genetic data from over 430,000 cohort study participants. Cardiovasc Diabetol. 2023; 22(1):306. PMC: 10633980. DOI: 10.1186/s12933-023-02045-6. View

16.

Zuo K, Yin X, Li K, Zhang J, Wang P, Jiao J . Different Types of Atrial Fibrillation Share Patterns of Gut Microbiota Dysbiosis. mSphere. 2020; 5(2). PMC: 7082137. DOI: 10.1128/mSphere.00071-20. View

17.

Wang M, Xiong H, Lu L, Zhu T, Jiang H . Serum Lipopolysaccharide Is Associated with the Recurrence of Atrial Fibrillation after Radiofrequency Ablation by Increasing Systemic Inflammation and Atrial Fibrosis. Oxid Med Cell Longev. 2022; 2022:2405972. PMC: 9588364. DOI: 10.1155/2022/2405972. View

18.

Geng J, Yang C, Wang B, Zhang X, Hu T, Gu Y . Trimethylamine N-oxide promotes atherosclerosis via CD36-dependent MAPK/JNK pathway. Biomed Pharmacother. 2017; 97:941-947. DOI: 10.1016/j.biopha.2017.11.016. View

19.

Yang W, Yang R, Zhao Q, Li X, Wang Y . A systematic review and meta-analysis of the gut microbiota-dependent metabolite trimethylamine N-oxide with the incidence of atrial fibrillation. Ann Palliat Med. 2021; 10(11):11512-11523. DOI: 10.21037/apm-21-2763. View

20.

Guasti L, Galliazzo S, Molaro M, Visconti E, Pennella B, Gaudio G . TMAO as a biomarker of cardiovascular events: a systematic review and meta-analysis. Intern Emerg Med. 2020; 16(1):201-207. DOI: 10.1007/s11739-020-02470-5. View